ArticleTranslational cancer research2026
Differentiating breast cancer lung metastasis from primary lung cancer using clinical and computed tomography radiomics features.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common malignancy in women globally and a leading cause of cancer-related death. This study aimed to differentiate breast cancer lung metastasis (BCLM) from primary lung cancer (PLC) in patients with breast cancer by integrating clinicopathological characteristics and computed tomography (CT) radiomics to develop and validate a predictive model. Methods: A total of 158 patients with breast cancer who were diagnosed with lung metastasis or PLC between 2013 and 2023 were retrospectively included. The patients were randomly assigned to a training group (n=111) and a testing group (n=47). Clinical data and CT images were collected. Independent predictors were identified using logistic regression analysis. Radiomics features were extracted from intratumoral, peritumoral, and combined regions using three-dimensional (3D) Slicer software. Results: There were 100 patients diagnosed with PLC, and 58 were diagnosed with BCLM. Patients in the BCLM group demonstrated higher tumor (T) stage, node (N) stage, human epidermal growth factor receptor 2 positivity, Ki-67 levels, and serum carbohydrate antigen 153 concentrations compared with those of the PLC group. The clinical model yielded an area under the curve (AUC) of 0.704 in the training group and 0.760 in the testing group. The radiomics models achieved AUC values ranging from 0.742 to 0.952. The combined model demonstrated AUC values of 0.959 in the training group and 0.946 in the testing group. Conclusions: A combined model incorporating clinical and radiomics features demonstrated high predictive performance for distinguishing BCLM from PLC, supporting improved diagnostic differentiation and clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.